ArticleOncology letters2019
miR-152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Systematic review of circulating MICRORNAS as biomarkers of cervical carcinogenesis.BMC cancer · 2022Pooled it
- miR-1307-3p promotes the progression of cervical cancer by targeting FOXO3.Irish journal of medical science · 2026Article
- The role and diagnostic value of deregulated miRNAs in cervical cancer.Discover oncology · 2025Review
- MicroRNA-Based Liquid Biopsy for Cervical Cancer Diagnostics and Treatment Monitoring.International journal of molecular sciences · 2024Review
- Performance of an ancillary test for cervical cancer that measures miRNAs and cytokines in serum and cervical mucus.Cancer science · 2024Article
- The diagnostic accuracy of serum and plasma microRNAs in detection of cervical intraepithelial neoplasia and cervical cancer: A systematic review andGynecologic oncology reports · 2024Article
- Expression of miR-152 in cervical cancer and its influence on cisplatin resistance.African health sciences · 2023Article
- Circulating cervical cancer biomarkers potentially useful in medical attention (Review).Molecular and clinical oncology · 2023Review
- Value of non-coding RNAs to assess lymph node status in cervical cancer.Frontiers in oncology · 2023Review
- The promotional effect of microRNA-103a-3p in cervical cancer cells by regulating the ubiquitin ligase FBXW7 function.Human cell · 2022Article
- microRNA Profile Associated with Positive Lymph Node Metastasis in Early-Stage Cervical Cancer.Current oncology (Toronto, Ont.) · 2022Article
- Role of Phosphatidylinositol 3-Kinase and Its Catalytic Unit PIK3CA in Cervical Cancer: A Mini-Review.Applied bionics and biomechanics · 2022Review
- Overexpression of miR-3653 is Associated with HPV Infection and Serves as a Biomarker in Patients with Cervical Cancer.International journal of women's health · 2022Article
- miR-153 enhances the therapeutic effect of radiotherapy by targeting JAG1 in pancreatic cancer cells.Oncology letters · 2021Article
- Small Non-Coding-RNA in Gynecological Malignancies.Cancers · 2021Review
- MicroRNA‑15a‑5p‑targeting oncogene YAP1 inhibits cell viability and induces cell apoptosis in cervical cancer cells.International journal of molecular medicine · 2020Article
- ADH7, miR-3065 and LINC01133 are associated with cervical cancer progression in different age groups.Oncology letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have demonstrated that circulating miRNAs are effective biomarkers of various types of cancer. It has also been indicated that miR-152 is upregulated in cervical cancer. However, whether miR-152 may be used as an early detection method for patients with cervical cancer is yet to be elucidated. The results of the current study demonstrated that miR-152 levels were the lowest in healthy controls, high in patients with cervical intraepithelial neoplasia (CIN), and the highest in patients with cervical cancer. Furthermore, miR-152 levels in peripheral blood were higher in patients with high-grade CIN compared with those with low-grade CIN. It was also demonstrated that miR-152 levels increased as the clinical stage of cervical cancer advanced. Compared with healthy controls, squamous cell carcinoma antigen (SSC-Ag) levels were significantly higher in patients with cervical cancer. However, no significant differences were identified in patients with CIN, indicating that SCC-Ag could not be used for the early detection of CIN. In contrast, miR-152 was elevated along with SCC-Ag in patients with CIN and cervical cancer. Receiver operating characteristic (ROC) analysis demonstrated that miR-152 preferentially distinguished patients with CIN (95% confidence interval, 0.688-0.973; P<0.001) and patients with cervical cancer (95% confidence interval, 0.817-0.996; P<0.001) from healthy controls. Additionally, miR-152 levels were markedly reduced in patients with cervical cancer who received chemotherapy (28 patients) or chemotherapy and radiation therapy (22 patients). In conclusion, the level of miR-153 in peripheral blood may be utilized as an effective biomarker for the early detection of cervical cancer, thus decreasing the requirement for invasive cervical biopsies. Furthermore, it may be utilized to predict the most effective form of treatment for patients with cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.